^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Cellgram-DC (autologous dendritic cell)

    i
    Other names: autologous dendritic cell anticancer immune cell therapy
    Associations

    News

    Trials
    Company:
    Pharmicell
    Drug class:
    Stem cell stimulant
    Related drugs:
    Associations

    News

    Trials
    almost2years
    Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) (clinicaltrials.gov)
    P1, N=3, Terminated, Pharmicell Co., Ltd. | N=10 --> 3 | Trial completion date: Dec 2022 --> Feb 2022 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> Feb 2022; Difficult recruitment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • IO biomarker • Metastases • Immune cell
    |
    CAST (Calpastatin)
    |
    Cellgram-DC (autologous dendritic cell)
    almost2years
    Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) (clinicaltrials.gov)
    P1, N=2, Terminated, Pharmicell Co., Ltd. | N=10 --> 2 | Trial completion date: Dec 2022 --> May 2022 | Recruiting --> Terminated | Trial primary completion date: Dec 2022 --> May 2022; Difficult recruitment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • IO biomarker • Metastases • Immune cell
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Cellgram-DC (autologous dendritic cell)
    3years
    Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) (clinicaltrials.gov)
    P1, N=10, Recruiting, Pharmicell Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Dec 2020 --> Nov 2021
    Clinical • Enrollment open • Trial initiation date • IO biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Cellgram-DC (autologous dendritic cell)
    4years
    Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC) (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Pharmicell Co., Ltd.
    Clinical • New P1 trial • IO biomarker
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    Cellgram-DC (autologous dendritic cell)